Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

• ClinicalTrials.gov Identifier: NCT03318861
• Recruitment Status: Terminated
• First Posted: October 24, 2017
• Results First Posted: May 26, 2020
• Last Update Posted: October 28, 2022
• Sponsor: Kite, A Gilead Company
• Information provided by (Responsible Party): Gilead Sciences ( Kite, A Gilead Company )

Study Description

Brief Summary:

The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limiting toxicities (DLTs). Participants will be given a 3 day course of conditioning chemotherapy followed by a single infusion of KITE-585.

Condition or disease	Intervention/treatment	Phase
Relapsed/Refractory Multiple Myeloma	Genetic: KITE-585; Drug: Cyclophosphamide; Drug: Fludarabine	Phase 1

Detailed Description:

Participants with relapsed/refractory multiple myeloma can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, ECG and echocardiogram of the heart, brain MRI, and blood draws. Eligible participants have white blood cells collected by leukapheresis. These cells are genetically modified to make the experimental treatment KITE-585. Participants receive conditioning chemotherapy prior to the KITE-585 infusion. After the KITE-585 infusion, participants will be followed for side effects and effect of KITE-585 on their myeloma. Study procedures may be performed while hospitalized and/or in the outpatient setting. Subjects who received an infusion of KITE-585 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 17 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Dose-Escalation and Dose Expansion
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma
• Actual Study Start Date: October 20, 2017
• Actual Primary Completion Date: May 19, 2019
• Actual Study Completion Date: September 16, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Dose Escalation: 3 x 10^7 KITE-585; Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 autologous anti-B-cell maturation antigen (BCMA) CAR T cells at a dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.	Genetic: KITE-585; A single infusion of KITE-585 autologous anti-BCMA CAR T cells; Drug: Cyclophosphamide; Administered intravenously; Drug: Fludarabine; Administered intravenously
Experimental: Dose Escalation: 1 x 10^8 KITE-585; Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.	Genetic: KITE-585; A single infusion of KITE-585 autologous anti-BCMA CAR T cells; Drug: Cyclophosphamide; Administered intravenously; Drug: Fludarabine; Administered intravenously
Experimental: Dose Escalation: 3 x 10^8 KITE-585; Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 3 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.	Genetic: KITE-585; A single infusion of KITE-585 autologous anti-BCMA CAR T cells; Drug: Cyclophosphamide; Administered intravenously; Drug: Fludarabine; Administered intravenously
Experimental: Dose Escalation: 1 x 10^9 KITE-585; Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^9 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.	Genetic: KITE-585; A single infusion of KITE-585 autologous anti-BCMA CAR T cells; Drug: Cyclophosphamide; Administered intravenously; Drug: Fludarabine; Administered intravenously
Experimental: Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585; RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min [Grade 2 chronic kidney disease]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 24 mg/m^2/day IV infusion for 3 days followed by a single intravenous infusion of KITE-585 anti-autologous BCMA CAR T cells at a tolerable dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.	Genetic: KITE-585; A single infusion of KITE-585 autologous anti-BCMA CAR T cells; Drug: Cyclophosphamide; Administered intravenously; Drug: Fludarabine; Administered intravenously

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) [ Time Frame: From KITE-585 infusion until 28 days after KITE-585 infusion ]

   A DLT is a KITE-585-related event with onset in the first 28 days following infusion. DLTs are defined by events and duration of events, including:

   • Any duration: Grade (GR) 4 cytokine release syndrome (CRS), KITE-585-related GR 5 adverse events (AE) and GR 4 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 3 or better in ≤ 72 hours, hypogammaglobulinemia, tumor lysis syndrome, acute renal toxicity requiring dialysis for ≤ 7 days, intubation for airway protection for ≤ 7 days and AE resolves to ≤ GR 1 within 2 weeks and baseline within 4 weeks
   • ≥ 72 hours: GR 3 CRS and GR 3 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 2 or better in ≤ 14 days, hypogammaglobulinemia and tumor lysis syndrome
   • ≥ 30 days: GR 4 hematologic AE with the exceptions of cytopenias attributable to ongoing or recurrent multiple myeloma

Secondary Outcome Measures :

1. Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria [ Time Frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months) ]
   ORR: Percentage of participants who achieved a stringent CR (sCR), complete response (CR), partial response (PR), or very good PR (VGPR), as determined by IMWG Consensus Panel 1 Criteria. sCR: CR+normal free light chain (FLC) ratio, no clonal cells in BM by immunohistochemistry or immunofluorescence; CR: negative immunofixation (IFX) on serum and urine, no soft tissue plasmacytomas (STP), <5% plasma cells in bone marrow (BM); PR: ≥50% decrease of serum M-protein + 24hr urinary M-protein decrease by ≥90% or <200 mg/24hr. If unmeasurable serum and urine M-protein; and serum-free light assay; requires ≥ 50% decrease in the difference between involved and uninvolved FLC levels / ≥ 50% reduction in plasma cells (PC), provided baseline BM PC percentage was ≥ 30%, respectively. If present at baseline, ≥ 50% reduction in the size of STP is also required; VGPR: serum and urine M-protein detected by IFX but not electrophoresis, >90% in serum M-protein+urine, M-protein level <100 mg/24hr.
2. Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1 [ Time Frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months) ]
   PFS: Interval from first study drug dose date to the earlier of first documentation of definitive progressive disease (PD) per IMWG Consensus Panel 1 Criteria or death from any cause. PD: an increase of 25% from the lowest response value in 1 of the following: Serum and urine M-protein (absolute increase ≥ 0.5 g/dL and ≥ 200 mg/24 hours, respectively); In participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase > 10 mg/dL); In participants without measurable serum and urine M-protein and without measurable disease by FLC levels, bone marrow PC percentage (absolute percentage ≥ 10%). Definite development of new bone lesions or STP or definite increase in the size of existing bone lesions or STPs; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. Analysis was done using Kaplan-Meier (KM) estimate.
3. Overall Survival (OS) [ Time Frame: From KITE-585 infusion to date of data cutoff (maximum: 17.6 months) ]
   Overall survival is defined as the time from the first dose date of study drug to the date of death from any cause. Analysis was done using KM estimate. Participants who have not died by the analysis data cutoff date were censored at their last date known to be alive or cutoff date, whichever is earlier.
4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events [ Time Frame: From KITE-585 infusion to date of data cutoff (maximum: 17.6 months) ]
5. Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities [ Time Frame: From KITE-585 infusion to date of data cutoff (maximum: 17.6 months) ]
   Clinically significant laboratory abnormalities were defined as per investigator's discretion.
6. Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1 [ Time Frame: From first response to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months) ]
   DOR is defined for participants who experience an objective response and is defined as the time from the date of their first objective response (which is subsequently confirmed) to PD per IMWG Consensus Panel 1 Criteria or death from any cause, whichever is earlier. Objective response is defined in Outcome measure 2. Analysis was done using KM estimate. Participants not meeting the criteria for PD by the analysis data cutoff date were censored at their last evaluable disease assessment date before any other anti-cancer therapies including stem cell transplant.
7. Time to Next Treatment (TTNT) [ Time Frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months) ]
   TTNT is defined as the length of time between the date of KITE-585 infusion to the date of initiation of the next therapy or death due to any cause, whichever is earlier. Analysis was done using KM estimate. Participants with no new anti-cancer therapy and alive by the time of data cutoff were censored at the last date known to be alive or cutoff date, whichever is earlier.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

1. Measurable relapsed or refractory myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

3. Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

   • Absolute neutrophil count (ANC) ≥ 1,000/µL
   • Platelet count ≥ 75,000/µL
   • Absolute lymphocyte count ≥ 100/µL
   • Creatinine clearance above limits set in the protocol for each cohort
   • Normal cardiac function as assessed by electrocardiogram (ECG) and echocardiogram
   • Baseline oxygen saturation > 92% on room air and no clinically significant pleural effusion

Key Exclusion Criteria:

1. Plasma cell leukemia
2. Non-secretory multiple myeloma
3. History of Central nervous system (CNS) involvement by multiple myeloma
4. Prior CAR therapy or other genetically modified T cells
5. Inadequate washout from prior therapy
6. Autologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant
7. History of active autoimmune disease
8. History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment
9. Recent history of other (non multiple myeloma) cancer
10. Active viral, fungal, bacterial or other infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Contacts and Locations

Locations

United States, California

David Geffen School of Medicine at UCLA

Los Angeles, California, United States, 90095

United States, Florida

H. Lee Moffitt Cancer Center

Tampa, Florida, United States, 33612

United States, Georgia

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States, 30322

United States, Illinois

University of Chicago Medical Center

Chicago, Illinois, United States, 60637

United States, Massachusetts

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02114

United States, Minnesota

Mayo Clinic

Rochester, Minnesota, United States, 55905

United States, New York

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

United States, Tennessee

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

United States, Texas

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Sponsors and Collaborators

Kite, A Gilead Company

Investigators

• Study Director: Kite Study Director; Kite, A Gilead Company

  Study Documents (Full-Text)

Documents provided by Gilead Sciences ( Kite, A Gilead Company ):

Study Protocol  [PDF] September 11, 2017

Statistical Analysis Plan  [PDF] March 26, 2019

More Information

Additional Information:

Gilead Clinical Trials Website 

• Responsible Party: Kite, A Gilead Company
• ClinicalTrials.gov Identifier: NCT03318861
• Other Study ID Numbers: KITE-585-501
• First Posted: October 24, 2017
• Results First Posted: May 26, 2020
• Last Update Posted: October 28, 2022
• Last Verified: October 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Multiple Myeloma; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Cyclophosphamide; Fludarabine; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists